Evidence map›Paper›PMID 35693292›Full record

ArticleTranslational lung cancer research2022

Single nucleotide polymorphisms in

Hailei Du, Rui Mu, Lihua Liu, Hongliang Liu, Sheng Luo, Edward F Patz, Carolyn Glass, Li Su, Mulong Du, David C Christiani and 2 more

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Translational lung cancer research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.3field-weighted citation impact, top 51% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 3 citations in OpenAlex.

  1. Circadian clock and cancer.Military Medical Research · 2026
    Review
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 5 institutions in 2 countries.

Hailei DuDepartment of Thoracic Surgery, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Rui MuDuke Cancer Institute, Duke University Medical Center, Durham, NC, USA.
Lihua LiuDuke Cancer Institute, Duke University Medical Center, Durham, NC, USA.
Hongliang LiuDuke Cancer Institute, Duke University Medical Center, Durham, NC, USA.
Sheng LuoDepartment of Biostatistics and Bioinformatics, Duke University School of Medicine, Durham, NC, USA.
Edward F PatzDuke Cancer Institute, Duke University Medical Center, Durham, NC, USA.
Carolyn GlassDuke Cancer Institute, Duke University Medical Center, Durham, NC, USA.
Li SuDepartments of Environmental Health and Epidemiology, Harvard TH Chan School of Public Health, Boston, MA, USA.
Mulong DuDepartments of Environmental Health and Epidemiology, Harvard TH Chan School of Public Health, Boston, MA, USA.
David C ChristianiDepartments of Environmental Health and Epidemiology, Harvard TH Chan School of Public Health, Boston, MA, USA.
Hecheng LiDepartment of Thoracic Surgery, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Qingyi WeiDuke Cancer Institute, Duke University Medical Center, Durham, NC, USA.
Duke University · USHarvard University · USGuangxi Medical University · CNMassachusetts Department of Public Health · USShanghai Jiao Tong University · CN

Funding

Women's Cancer Research ProgramP30CA014236 · NCI · DUKE UNIVERSITY · PI JOHN N. NORTON · 1985 to 2026
$174.8M
The Boston Lung Cancer Survival CohortU01CA209414 · NCI · HARVARD UNIVERSITY D/B/A HARVARD SCHOOL OF PUBLIC HEALTH · PI David C Christiani · 2017 to 2026
$12.2M
Translational studies of Hsp90 inhibitors in NSCLCP50CA090578 · NCI · DANA-FARBER CANCER INST · PI YEAP, BEOW Y · 2008 to 2012
$11.4M
Statistical Methods for Analysis of Massive Genetic and Genomic Data in Cancer ResearchR35CA197449 · NCI · HARVARD UNIVERSITY D/B/A HARVARD SCHOOL OF PUBLIC HEALTH · PI XIHONG LIN · 2015 to 2026
$10.9M
Molecular and Genetic Analysis of Lung Cancer SurvivalR01CA092824 · NCI · HARVARD UNIVERSITY (SCH OF PUBLIC HLTH) · PI CHRISTIANI, DAVID C · 2002 to 2013
$5.9M
SPORE in Lung CancerP20CA090578 · NCI · DANA-FARBER CANCER INSTITUTE · PI JOHNSON, BRUCE E. · 2003 to 2007
$5.1M
GENETIC SUSCEPTIBILITY TO LUNG CANCERR01CA074386 · NCI · HARVARD UNIVERSITY (SCH OF PUBLIC HLTH) · PI CHRISTIANI, DAVID C · 1997 to 2008
$4.8M
NCI NIH HHS P20 CA090578NCI NIH HHS P30 CA014236NCI NIH HHS P50 CA090578NCI NIH HHS R01 CA074386NCI NIH HHS R01 CA092824NCI NIH HHS R35 CA197449NCI NIH HHS U01 CA209414
6 · The paper itself

Abstract

Background: Lymphocyte activation is part of a complex microenvironment that affects the development and progression of solid tumors. The present study analyzed the associations between genetic variants in lymphocyte activation-related genes and survival of patients with non-small cell lung cancer (NSCLC). Methods: Our study evaluated the associations of 14,400 (1,599 genotyped and 12,801 imputed) single-nucleotide polymorphisms (SNPs) in 176 lymphocyte activation pathway-related genes with survival of 1,185 NSCLC patients in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial and validated the results in another independent dataset of 984 NSCLC patients from the Harvard Lung Cancer Susceptibility (HLCS) trial. Results: Multivariable Cox proportional hazards regression analyses identified two distinct and possibly functional variants in forkhead box P1 ( Conclusions: Genetic variants in

Indexed as

lymphocyte activationNon-small cell lung cancer (NSCLC)single-nucleotide polymorphismsurvival

Identifiers

PMID35693292
PMCPMC9186164
OpenAlexW4282915592

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.